More than half of 23-year-olds in a European study show restrictive, emotional or uncontrolled eating behaviors, according to new research led by the Institute of
Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these drugs to those who
For years now, companies behind weight loss drugs like Wegovy and Zepbound have been trying to convince the medical community and the public that obesity
In blood cancers such as chronic lymphocytic leukaemia, B cells of the immune system multiply uncontrollably.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s
Business of Health Care Reporter Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses
Climb Bio is currently conducting IND-enabling studies for the therapy. Credit: PeopleImages.com – Yuri A / Shutterstock. Climb Bio has entered an exclusive licence agreement
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Ready for
Patrizia Cavazzoni, leader of the Food and Drug Administration’s Center for Drug Evaluation and Research, is leaving the agency on Jan. 18, the latest top
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already